Outcomes of heart transplantation in cardiac amyloidosis: an updated systematic review
- PMID: 35595919
- DOI: 10.1007/s10741-022-10252-8
Outcomes of heart transplantation in cardiac amyloidosis: an updated systematic review
Abstract
Cardiac amyloidosis is one of the most common infiltrative cardiomyopathies that is characterized by the extracellular deposition of misfolded fibrillar protein. Several studies have previously found that patients with amyloid in the past have performed poorly after heart transplantation. Recent advancements in treatments have been made that have significantly improved outcomes in these patients. The study aimed to evaluate the outcomes of heart transplantation in cardiac amyloidosis. We systematically searched EMBASE, PubMed/MEDLINE, and Cochrane Library databases on 30 December 2021 following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. We identified 22 studies that examined 42,951 patients with cardiac amyloidosis of which only 1,329 patients underwent isolated heart transplantation. Seven studies reported individual patient data. The results of 123 patients have been pooled for analysis. There were 70 male patients, 45 female patients, and eight patients who did not report their gender. Among the types of amyloids, 63 (51%) patients were found to have light chain amyloidosis (AL) and 33 (27%) patients had transthyretin amyloidosis (ATTR). Only 41 patients (33.3%) reported a monoclonal component. There were 30 patients with AL that underwent autologous hematopoietic stem cell transplant (ASCT). The mean survival of 24 out of 30 patients was 4.33 years. In addition, the reported data include 13 patients requiring intra-aortic balloon pump (IABP), six with cardiac resynchronization therapy (CRT), and four with implantable cardioverter defibrillator (ICD). With the current advancements in treatments in combination with a multidisciplinary approach and careful patient selection, patients undergoing heart transplantation for amyloidosis may have encouraging results in the current era. Further studies will be needed to evaluate the outcomes of heart transplantation in amyloidosis patients now that several advances have been made in the field.
Keywords: Cardiac amyloidosis; Heart failure; Heart transplantation; Infiltrative cardiomyopathy.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Heart transplantation in end-stage heart failure secondary to cardiac sarcoidosis: an updated systematic review.Heart Fail Rev. 2023 Jul;28(4):961-966. doi: 10.1007/s10741-022-10284-0. Epub 2022 Nov 10. Heart Fail Rev. 2023. PMID: 36355274
-
Sertindole for schizophrenia.Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2. Cochrane Database Syst Rev. 2005. PMID: 16034864 Free PMC article.
-
Psychological and/or educational interventions for the prevention of depression in children and adolescents.Cochrane Database Syst Rev. 2004;(1):CD003380. doi: 10.1002/14651858.CD003380.pub2. Cochrane Database Syst Rev. 2004. Update in: Cochrane Database Syst Rev. 2011 Dec 07;(12):CD003380. doi: 10.1002/14651858.CD003380.pub3. PMID: 14974014 Updated.
-
Comparison of cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease.Cochrane Database Syst Rev. 2001;(3):CD003234. doi: 10.1002/14651858.CD003234. Cochrane Database Syst Rev. 2001. Update in: Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003234. doi: 10.1002/14651858.CD003234.pub2. PMID: 11687058 Updated.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
Cited by
-
Cardiac Amyloidosis: State-of-the-Art Review in Molecular Pathology.Curr Issues Mol Biol. 2024 Oct 16;46(10):11519-11536. doi: 10.3390/cimb46100684. Curr Issues Mol Biol. 2024. PMID: 39451564 Free PMC article. Review.
-
Amyloids and the Heart: An Update.J Clin Med. 2024 Nov 27;13(23):7210. doi: 10.3390/jcm13237210. J Clin Med. 2024. PMID: 39685666 Free PMC article. Review.
References
-
- Blancas-Mejía LM, Ramirez-Alvarado M (2013) Systemic amyloidosis. Annu Rev Biochem 82:745–74. https://doi.org/10.1146/annurev-biochem-072611-130030 . (Epub 2013 Feb 28. PMID: 23451869; PMCID: PMC4044913)
-
- González-López E, López-Sainz Á, Garcia-Pavia P (2017) Diagnosis and treatment of transthyretin cardiac amyloidosis. Progress and Hope Rev Esp Cardiol (Engl Ed) 70(11):991–1004. https://doi.org/10.1016/j.rec.2017.05.036 - DOI
-
- Tahir UA, Doros G, Kim JS et al (2019) Predictors of mortality in light chain cardiac amyloidosis with heart failure. Sci Rep 9(1):8552. https://doi.org/10.1038/s41598-019-44912-x . (Published 12 Jun 2019)
-
- Ruberg FL, Grogan M, Hanna M et al (2019) Transthyretin amyloid cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol 73(22):2872–2891. https://doi.org/10.1016/j.jacc.2019.04.003.PMID:31171094;PMCID:PMC6724183 - DOI - PubMed - PMC
-
- Kittleson MM, Maurer MS, Ambardekar AV et al (2021) Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association [published correction appears in Circulation 144(1):e11]. Circulation 142(1):e7-e22. https://doi.org/10.1161/CIR.0000000000000792
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous